Caribou Biosciences, Inc.
NASDAQ:CRBUBiotechnology
Healthcare
$0.49 -2.74%
-$0.05 today
- Market cap
- $52.47M
- Beta
- 2.33
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.39
52W Low $1.20High $3.54
Volume 1.01M
Average 1.83M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$110.99M
FY 2025 · Annual
Investing Cash Flow
$102.24M
FY 2025 · Annual
+18.0% YoYFinancing Cash Flow
$4.82M
FY 2025 · Annual
-71.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (66.92M) | (99.42M) | (102.07M) | (149.11M) | (148.13M) |
| Depreciation & Amortization | 984K | 3.64M | 3.53M | 3.93M | 3.65M |
| Deferred Income Tax | 0 | (95K) | 0 | 0 | (548K) |
| Stock-Based Compensation | 3.45M | 11.72M | 13.75M | 16.71M | 12.68M |
| Change in Working Capital | 29.07M | (4.11M) | (7.32M) | (5.11M) | (484K) |
| Accounts Receivables | (2.96M) | 3.46M | 805K | 608K | 272K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.14M | (2.72M) | 1.82M | (354K) | 3.25M |
| Other Working Capital | 30.89M | (4.85M) | (9.94M) | (5.37M) | (4.01M) |
| Other Non-Cash Items | 904K | 9.02M | (1.18M) | (4.61M) | 21.84M |
| Operating Cash Flow | (32.52M) | (90.97M) | (93.29M) | (138.2M) | (110.99M) |
| Capital Expenditures | (3.12M) | (6.45M) | (11.61M) | (6.51M) | (1.36M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (173.28M) | (339.06M) | (394.76M) | (304.39M) | (150.37M) |
| Sales of Investments | 0 | 252.87M | 338.19M | 397.49M | 252.83M |
| Other Investing Activities | (1M) | (600K) | 0 | (1.61M) | 1.14M |
| Investing Cash Flow | (176.4M) | (93.25M) | (68.18M) | 86.61M | 102.24M |
| Debt Repayment | 1.03M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 321.02M | 2.13M | 152.72M | 15.19M | 4.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.55M | 0 | 1.58M | 1.53M | 0 |
| Financing Cash Flow | 433.43M | 2.13M | 154.3M | 16.72M | 4.82M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 224.51M | (182.08M) | (7.18M) | (34.87M) | (3.93M) |
| Free Cash Flow | (35.64M) | (97.42M) | (104.9M) | (144.71M) | (112.35M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$148.1M
+ D&A$3.6M
+ Stock-Based Comp$12.7M
- Deferred Tax-$548.0K
- Working Capital-$484.0K
+ Other Non-Cash$21.8M
= Operating Cash Flow-$111.0M
- Capex-$1.4M
= Free Cash Flow-$112.4M
Analysis
FY2025 free cash flow is -$112.4M. FCF conversion is 75.8% of net income. Operating cash flow was -$111.0M, with capex of -$1.4M. The largest bridge item is Other Non-Cash at $21.8M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Oct 6, 2026 | |
| 8-K | Current report | Aug 13, 2026 | |
| 10-Q | Quarterly report | Aug 13, 2026 | |
| SC 13G | SC 13G filing | Jul 27, 2026 | |
| 8-K | Current report | Jun 18, 2026 |
Does CRBU generate free cash flow?
Caribou Biosciences, Inc. (CRBU) generated -$112.35M of free cash flow in fiscal 2025.
How much operating cash flow does CRBU produce?
Operating cash flow was -$110.99M, before capital expenditures of $1.36M.
Continue the stock analysis
Jump to another research area for this company.